Biotest is pleased to continue the development of BT-061 together with Abbott, one of the globe leaders in the commercialization and development of biologic medications for the treating immunological diseases, emphasized Prof. Dr. Gregor Schulz, CEO of Biotest AG. Using its tremendous encounter in the field and its global commercial power and presence, Abbott may be the ideal partner for maximizing the business and therapeutic potential of BT-061. Under the terms of the agreement, Abbott and Biotest will co-promote BT-061 in the five major European markets and Abbott will have exclusive global rights to commercialize BT-061 outdoors those countries.At each clinic visit, all patients underwent a total physical examination and security assessment, and bloodstream was taken for virologic and biochemical analysis. Safety and Efficacy Safety was assessed by the study investigators on the basis of adverse events reported spontaneously by research participants. In addition, plasma samples had been routinely assessed for hematologic variables . Outcome measures are described at length in the Supplementary Appendix. Statistical Analysis Detailed information on the procedures used for the statistical analysis is available in the Supplementary Appendix. In short, an intention-to-treat efficacy analysis was performed for all individuals receiving at least one dosage of the study medication .